CalciMedica, Inc.

CALC

US38942Q2021

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-07-11 EDT			5-day change	1st Jan Change
4.89 ^USD	+3.60%		+10.14%	+70.98%

07-10	Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained	MT
07-09	CalciMedica Says First Person Dosed in Phase 2 Trial of Auxora to Treat Acute Kidney Injury	MT

CalciMedica, Inc.(NasdaqCM:CALC) added to Russell 3000E Index

July 30, 2024

Latest news about CalciMedica, Inc.

Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained	07-10	MT
CalciMedica Says First Person Dosed in Phase 2 Trial of Auxora to Treat Acute Kidney Injury	07-09	MT
CalciMedica Inc. Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora? in Severe Acute Kidney Injury	07-09	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to Russell Microcap Growth Index	06-30	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to Russell 3000E Index	06-30	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to Russell Microcap Index	06-30	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to Russell 3000E Growth Index	06-30	CI
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora? in Acute Pancreatitis	06-27	CI
CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis	04-24	CI
Top Premarket Decliners	04-01	MT
CalciMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
CalciMedica Inc. Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International Acute Kidney Injury At the 29th International Aki & CRRT Conference	03-13	CI
JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22	02-16	MT
CalciMedica Gets FDA Nod for Phase 2 Trial of Acute Kidney Injury With Respiratory Failure Treatment	02-13	MT
Calcimedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora? for the Treatment of Severe Acute Kidney Injury	02-13	CI
CalciMedica, Inc. announced that it has received $20.252897 million in funding	02-04	CI
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target	01-29	MT
Calcimedica Insider Bought Shares Worth $2,515,080, According to a Recent SEC Filing	01-26	MT
CalciMedica Secures $55 Million Funding Deal With Investors; Shares Gain	01-22	MT
CalciMedica, Inc. announced that it expects to receive $20.4 million in funding	01-18	CI
CalciMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Top Premarket Decliners	11-07	MT
CalciMedica Inc. Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition	11-02	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to S&P TMI Index	23-09-18	CI

CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.88 USD

Average target price

18.33 USD

Spread / Average Target

+275.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CALCIMEDICA, INC.	+70.98%	51.7M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs

CalciMedica, Inc.

Equities

CALC

US38942Q2021

Biotechnology & Medical Research

CalciMedica, Inc.(NasdaqCM:CALC) added to Russell 3000E Index

Latest news about CalciMedica, Inc.

Chart CalciMedica, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs